BMS iza-bren 5 trials

ESMO: Bristol Myers CMO touts '5 out of 5' positive phase 3 trials for bispecific ADC iza-bren

Bristol Myers Squibb's CMO highlighted five consecutive positive Phase 3 trials for its bispecific ADC iza-bren, showing significant progression-free survival benefits in lung and breast cancers. Glob